Moscow Exchange · OZPH · IFRS
Ozon Pharmaceuticals: revenue, profit and cash flow
In 2025, Ozon Pharmaceuticals had revenue of ₽31.6B and a net profit of ₽6.17B, according to its consolidated IFRS statements. Here: 4 years of annual reports since 2022, each linked to the original document.
Revenue, 2025
change against 2024
Where the money goes
Of every ₽100 of revenue in 2025, Ozon Pharmaceuticals spent ₽52.3 on the cost of its products and services and ₽13.6 on running the business (₽11.9 of it on selling and administration); ₽5.9 went to income tax, ₽8.7 went to interest and other items, and ₽19.5 was left as net profit.
| In 2025 | Amount | Of revenue |
|---|---|---|
| Revenue | ₽31.6B | 100.0% |
| Cost of revenue | −₽16.5B | 52.3% |
| Gross profit | ₽15.1B | 47.7% |
| Sales & admin | −₽3.77B | 11.9% |
| Other operating | −₽520M | 1.6% |
| Operating profit | ₽10.8B | 34.1% |
| Income tax | −₽1.86B | 5.9% |
| Interest and other, net | −₽2.75B | 8.7% |
| Net profit | ₽6.17B | 19.5% |
In 2025, Ozon Pharmaceuticals took in ₽3.25B of cash from its operations. Of every ₽100 of it, it spent ₽60.2 on capital expenditure and ₽33.0 on dividends. The remaining ₽6.8 was left for other uses: repaying debt, investments or the cash balance.
| In 2025 | Amount | Of operating cash |
|---|---|---|
| Operating cash flow | ₽3.25B | 100.0% |
| Capital expenditure | −₽1.96B | 60.2% |
| Free cash flow | ₽1.29B | 39.8% |
| Dividends | −₽1.07B | 33.0% |
| Left over | ₽220M | 6.8% |
Revenue and net profit
Revenue went from ₽19B in 2022 to ₽31.6B in 2025.
Earnings per share
Basic earnings per share went from ₽3.65 in 2022 to ₽5.44 in 2025.
Number of shares
The weighted average number of ordinary shares went from 1.0B in 2022 to 1.14B in 2025.
Operating cash flow, capex and free cash flow
Free cash flow (operating cash flow minus capital expenditure) was ₽1.29B in 2025, 4.1% of revenue. Negative in 2022.
What it owns and who paid for it
At the end of 2025, Ozon Pharmaceuticals had ₽53.2B of assets, ₽2.83B of it in cash. They were paid for by ₽11.8B of borrowings, ₽8.23B of other liabilities and ₽33.2B of shareholders' equity: equity is 62.4% of the assets.
Net debt
Net debt (borrowings minus cash) was ₽8.97B at the end of 2025. That is 0.7 times its EBITDA of ₽12B (operating profit plus depreciation and amortisation).
Dividends paid
In 2025, Ozon Pharmaceuticals paid ₽1.07B in dividends, 17% of its net profit for the year.
The charts could not be loaded; the table below has the same numbers.
Ozon Pharmaceuticals: annual figures
| Year | Revenue | Operating profit | Net profit | Basic EPS | Operating cash flow | Capital expenditure | Free cash flow | Net debt | Dividends paid | Total assets | Equity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | ₽31.6B | ₽10.8B | ₽6.17B | ₽5.44 | ₽3.25B | ₽1.96B | ₽1.29B | ₽8.97B | ₽1.07B | ₽53.2B | ₽33.2B |
| 2024 | ₽25.6B | ₽7.94B | ₽4.61B | ₽4.46 | ₽5.83B | ₽2.46B | ₽3.37B | ₽9.95B | ₽1.5B | ₽49.5B | ₽25.3B |
| 2023 | ₽19.7B | ₽6.15B | ₽4.0B | ₽4.00 | ₽4.66B | ₽602M | ₽4.06B | ₽8.66B | ₽1.63B | ₽34.1B | ₽17.1B |
| 2022* | ₽19B | ₽5.5B | ₽3.65B | ₽3.65 | −₽994M | ₽562M | −₽1.56B | ₽10.3B | ₽1.29B | ₽34.1B | ₽14.7B |
* Taken from the comparative column of the next year's report: the year's own report was not available to us.
Original reports
Every figure on this page comes from the company's own annual statements. The documents, by year:
How to read these numbers
- A year's figures are as first reported. Companies sometimes restate the previous year in their next report (new accounting standards, discontinued operations); the original documents show both versions.
Source: annual financial statements published by Ozon Pharmaceuticals (links to the original documents above). Figures read from the documents by BigCapital.
For information only, not investment advice.